The pharmaceutical industry’s relentless pursuit of effective treatments for complex diseases drives constant innovation in chemical synthesis. The development of targeted therapies, such as Erlotinib for cancer treatment, relies heavily on the availability of specialized, high-purity chemical intermediates. Among these, 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline (CAS: 183377-18-1) plays a critical role, serving as a foundational component in the intricate synthetic pathways leading to the final Active Pharmaceutical Ingredient (API). This article explores the chemical characteristics and indispensable function of this compound in modern API manufacturing.

Chemically, 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline is defined by its molecular formula C14H17ClN2O4 and a molecular weight of 312.75. It is typically supplied as a white to off-white crystalline powder, a physical characteristic that facilitates its handling and processing in controlled manufacturing environments. The stringent purity specifications, often exceeding 99%, are crucial, as any impurities can potentially carry through the synthesis and affect the final API’s efficacy, safety, or regulatory compliance. Understanding these specifications, including limits on water content and other impurities, is paramount for R&D scientists and quality control teams.

The primary significance of 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline lies in its indispensable role as an intermediate for Erlotinib. Erlotinib, an EGFR inhibitor, is a vital drug in the oncology arsenal. The specific arrangement of functional groups within 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline – particularly the chlorine atom and the bis(2-methoxyethoxy) substituents on the quinazoline ring – makes it an ideal precursor for the key chemical transformations required to construct the Erlotinib molecule. This means that the consistent and high-quality supply of this intermediate is directly linked to the reliable production of Erlotinib itself.

For researchers and manufacturers looking to procure this compound, identifying reliable suppliers is key. Manufacturers specializing in fine chemicals and pharmaceutical intermediates, particularly those based in China, often offer competitive pricing and large-scale production capabilities. When seeking to purchase 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline, engaging with a supplier who can provide detailed technical data, batch consistency, and excellent customer support is vital. This includes understanding the availability of samples for testing, pricing structures for various quantities, and the overall reliability of the supply chain.

The pharmaceutical industry is constantly evolving, with a growing demand for advanced therapies. Intermediates like 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline are the unsung heroes in this progress, enabling the synthesis of complex drugs that improve patient lives. By focusing on quality, consistency, and strategic sourcing from experienced manufacturers, the industry can ensure the continued development and availability of essential treatments like Erlotinib.